Discordance analysis and the Gordian Knot of LDL and non-HDL cholesterol versus apoB

Current Opinion in Lipidology

Volumn 25, Issue 6, 2014, Pages 461-467

  Sniderman, Allan D ^a   Lamarche, Benoit ^b   Contois, John H ^c   De Graaf, Jacqueline ^d  

^a ROYAL VICTORIA HOSPITAL   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

^c Sun Diagnostics LLC   (United States)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Apolipoprotein B; Discordance analysis; LDL particle number; LDL cholesterol; Non HDL cholesterol

Indexed keywords

APOLIPOPROTEIN B; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; BIOLOGICAL MARKER; CHOLESTEROL ESTER; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ANALYTIC METHOD; ASSAY; CARDIOVASCULAR RISK; COST; HUMAN; PRIORITY JOURNAL; RELIABILITY; REVIEW; BLOOD; CARDIOVASCULAR DISEASE; RISK FACTOR; STATISTICAL MODEL;

APOLIPOPROTEINS B; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CHOLESTEROL ESTERS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CHOLESTEROL, VLDL; HUMANS; MODELS, STATISTICAL; RISK FACTORS; TRIGLYCERIDES;

EID: 84927649386     PISSN: 09579672     EISSN: 14736535     Source Type: Journal    
DOI: 10.1097/MOL.0000000000000127     Document Type: Review

References (23)

1. Sniderman AD, deGraaf J, Couture P. ApoB and the ApoB atherogenic dyslipoproteinemias. In: Kwiterovich PO, editor. The Johns Hopkins textbook of dyslipidemia. China: Wolter Kluwer; 2009. pp. 196-210.
2. Sniderman AD, Williams K, Contois JH, et al. A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. Circ Cardiovasc Qual Outcomes 2011; 4:337-345.
3. Di Angelantonio E, Sarwar N, Perry P, et al., Emerging Risk Factors Collaboration. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009; 302:1993-2000.
4. Di Angelantonio E, Gao P, Pennells L, et al., Emerging Risk Factors Collaboration. Lipid-related markers and cardiovascular disease prediction. JAMA 2012; 307:2499-2506.
5. Reiner Z, Catapano AL, De Backer G, et al. ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011; 32:1769-1818.
6. Anderson TJ, Grégoire J, Hegele RA, et al. 2012 update of the Canadian Cardiovascular Society Guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol 2013; 29:151-167.
7. JBS3 Board. Joint British Societies' consensus recommendations for the prevention of cardiovascular disease (JBS3). Heart 2014; 100 (Suppl 2):ii1-ii67.
8. Expert Dyslipidemia Panel of the International Atherosclerosis Society Panel members. An International Atherosclerosis Society Position Paper: global recommendations for the management of dyslipidemia-full report. J Clin Lipidol 2014; 8:29-60.
9. Sniderman AD, St-Pierre AC, Cantin B, et al. Concordance/discordance between plasma apolipoprotein B levels and the cholesterol indexes of atherosclerotic risk. Am J Cardiol 2003; 91:1173-1177.
10. Martin SS, Michos ED. Are we moving towards concordance on the principle that lipid discordance matters? Circulation 2014; 129:539-541.
11. Sniderman A, McQueen M, Contois J, et al. Why is non-high-density lipoprotein cholesterol a better marker of the risk of vascular disease than low-density lipoprotein cholesterol? J Clin Lipidol 2010; 4:152-155.
12. Sniderman AD, Jungner I, Holme I, et al. Errors that result from using the TC/HDL C ratio rather than the ApoB/ApoA-I ratio to identify the lipoproteinrelated risk of vascular disease. J Intern Med 2006; 259:455-461.
13. Cromwell WC, Otvos JD, Keyes MJ, et al. LDL particle number and risk of future cardiovascular disease in the Framingham Offspring Study: implications for LDL management. J Clin Lipidol 2007; 1:583-592.
14. Mora S, Buring JE, Ridker PM. Discordance of low-density lipoprotein (LDL) cholesterol with alternative LDL-related measures and future coronary events. Circulation 2014; 129:553-561.
15. Otvos JD, Mora S, Shalaurova I, et al. Clinical implications of discordance between low-density lipoprotein cholesterol and particle number. J Clin Lipidol 2011; 5:105-113.
16. Sniderman AD, Islam S, Yusuf S, McQueen MJ. Discordance analysis of apolipoprotein B and non-high density lipoprotein cholesterol as markers of cardiovascular risk in the INTERHEART study. Atherosclerosis 2012; 225:444-449.
17. Sniderman AD, Islam S, Yusuf S, McQueen MJ. Is the superiority of ApoB over Non-HDL-C as a marker of cardiovascular risk in the INTERHEART study due to confounding by related variables? J Clin Lipid 2013; 7:626-631.
18. Contois JH, McConnell JP, Sethi AA, et al., AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices. Apolipoprotein B and cardiovascular disease risk: position statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices. Clin Chem 2009; 55:407-419.
19. Cole TG, Contois JH, Csako G, et al. Association of apolipoprotein B and nuclear magnetic resonance spectroscopy-derived LDL particle number with outcomes in 25 clinical studies: assessment by the AACC Lipoprotein and Vascular Diseases Division Working Group on Best Practices. Clin Chem 2013; 59:752-770.
20. Marcovina SM, Albers JJ, Dati F, et al. International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. Clin Chem 1991; 37:1676-1682.
21. Marcovina SM, Albers JJ, Kennedy H, et al. International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. IV. Comparability of apolipoprotein B values by use of international reference material. Clin Chem 1994; 40:586-592.
22. Sniderman A, Couture P, de Graaf J. Diagnosis and treatment of apolipoprotein B dyslipoproteinemias. Nat Rev Endocrinol 2010; 6:335-346.
23. Thanassoulis G, Williams K, Ye K, et al. Relations of change in plasma levels of LDL-C, non-HDL-C and ApoB with risk reduction from Statin therapy: a metaanalysis of randomized trials. J Am Heart Assoc 2014; 3:e000759.